Investigational Drug Information for ABL001
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the drug development status for ABL001?
ABL001 is an investigational drug.
There have been 19 clinical trials for ABL001.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 6th 2021.
The most common disease conditions in clinical trials are Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Novartis Pharmaceuticals, National OncoVenture, and ABL Bio, Inc.
There are five US patents protecting this investigational drug and one hundred and ninety international patents.
Summary for ABL001
| US Patents | 5 |
| International Patents | 190 |
| US Patent Applications | 86 |
| WIPO Patent Applications | 65 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 1 (2021-10-06) |
| Vendors | 22 |
Recent Clinical Trials for ABL001
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) | Novartis Pharmaceuticals | Phase 3 |
| A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | Novartis Pharmaceuticals | Phase 2 |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for ABL001
Top disease conditions for ABL001
Top clinical trial sponsors for ABL001
US Patents for ABL001
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ABL001 | ⤷ Sign Up | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| ABL001 | ⤷ Sign Up | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| ABL001 | ⤷ Sign Up | Antibody molecules to PD-L1 and methods of treating cancer | Novartis AG (Basel, CH) Dana-Farber Cancer Institute, Inc. (Boston, MA) President and Fellows of Harvard College (Cambridge, MA) | ⤷ Sign Up |
| ABL001 | ⤷ Sign Up | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | Novartis AG (Basel, CH) | ⤷ Sign Up |
| ABL001 | ⤷ Sign Up | Antibody molecules to PD-L1 and uses thereof | Novartis AG (Basel, CH) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ABL001
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ABL001 | Argentina | AR111485 | 2037-04-20 | ⤷ Sign Up |
| ABL001 | Argentina | AR114366 | 2037-04-20 | ⤷ Sign Up |
| ABL001 | Australia | AU2018256423 | 2037-04-20 | ⤷ Sign Up |
| ABL001 | Australia | AU2019222644 | 2037-04-20 | ⤷ Sign Up |
| ABL001 | Australia | AU2021200639 | 2037-04-20 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
